Corona Remedies Ltd Company Summary

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited, a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited. A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).

The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in womens healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer division in year 2010; launched Xemx (multispeciality) division in 2005. The production of first manufacturing plant was commissioned at Solan, Himachal Pradesh in 2007.

The Company launched Gynaecology division in 2008; further launched Cardioloy division in 2013; launched Cardiovascular disease (CVD) and Solis division in 2016. Later, the production at Ahmedabad Plant commissioned in Gujarat in 2021. Radiance and Solaris Divisions launched in 2022; followed by Urology division in 2023.

The Company acquired the Myoril brand from Sanofi Healthcare India Private Limited in strengthening the pain management portfolio in 2024. Company issued 6,174,051 equity shares of face value of Rs 10, by raising Rs 655.37 crore through offer for sale on December 10, 2025. In FY25-26, Company acquired 7 brands from Bayer Zydus Pharma Ltd.

It acquired Wokadine from Dr. Reddys Laboratories Ltd, by entering into a new therapeutic area of Povidone Iodine. Moreover, Company strengthened womens health through engagement with infertility specialists, IVF focused chain hospitals and enhanced MR coverage.

Certification has been received for Gujarat Facility in Jan 2026, unlocking opportunities in 5 Key Eurasian markets.